VistaGen Therapeutics Inc (VTGN : NASDAQ)
Common Stock
$0.37
USD
+0.12 (46.54%)
Last updated: 2026-09-23
Follow VTGN
VTGN
VistaGen Therapeutics Inc
WealthAwesomePerformance
1 Day
+46.54%
1 Week
+59.76%
1 Month
+53.50%
YTD
-46.61%
Key Statistics
Market Cap
$11.16M
52W High
$5.14
52W Low
$0.20
P/E Ratio
-
50 Day MA
$0.25
200 Day MA
$0.69
Beta
0.39
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/23/2026 | $0.39 | $0.55 | $0.34 | $0.37 | $0.37 | 570,402,451 |
| 9/22/2026 | $0.25 | $0.27 | $0.24 | $0.25 | $0.25 | 5,898,275 |
| 9/21/2026 | $0.24 | $0.24 | $0.23 | $0.23 | $0.23 | 332,011 |
| 9/18/2026 | $0.23 | $0.25 | $0.23 | $0.24 | $0.24 | 718,200 |
| 9/17/2026 | $0.24 | $0.24 | $0.23 | $0.23 | $0.23 | 361,249 |
| 9/16/2026 | $0.24 | $0.24 | $0.23 | $0.23 | $0.23 | 553,566 |
| 9/15/2026 | $0.25 | $0.25 | $0.24 | $0.24 | $0.24 | 194,400 |
| 9/14/2026 | $0.25 | $0.25 | $0.24 | $0.24 | $0.24 | 238,800 |
| 9/11/2026 | $0.24 | $0.25 | $0.23 | $0.24 | $0.24 | 310,000 |
| 9/10/2026 | $0.24 | $0.24 | $0.23 | $0.24 | $0.24 | 339,900 |
Analyst Price Targets
Based on 4 analysts covering VTGN · as of Sep 17, 2026
Wall Street analysts forecast VTGN stock price to rise 171.4% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
US$1.00
+171.4% Upside
Current Price
US$0.37
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VTGN's historical volatility
30-Day Vol
124.6%
Annualized
90-Day Vol
255.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$0.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.35 | US$0.23 – US$0.53 |
| 60 trading days | US$0.33 | US$0.18 – US$0.60 |
| 90 trading days | US$0.31 | US$0.15 – US$0.65 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Financials
- Revenue (TTM)
- $2.50M
- EBITDA
- $-69.46M
- Profit Margin
- 0.00%
- ROE (TTM)
- -166.46%
- EPS (Diluted)
- -1.82
- Book Value
- 0.55
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About VTGN.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| BENF | Beneficient Class A Common Stock | $2.90 | +438.73% |
| JAGX | Jaguar Animal Health Inc | $8.91 | +233.71% |
| WHLR | Wheeler Real Estate Investment Trust, Inc. | $5.44 | +190.91% |
| VSA | TCTM Kids IT Education Inc. | $3.64 | +83.84% |
| ARTL | Artelo Biosciences Inc | $7.31 | +76.14% |
| BFRG | Bullfrog AI Holdings, Inc. Common Stock | $0.95 | +58.33% |
| IPDN | Professional Diversity Network Inc | $5.42 | +38.97% |
| ONCO | Onconetix Inc | $0.91 | +38.93% |